Evaluation of a rapid and simple placental growth factor test in hypertensive disorders of pregnancy

Hypertension Research

Volumn 36, Issue 5, 2013, Pages 457-462

  Gullai, Nóra ^a   Stenczer, Balázs ^a   Molvarec, Attila ^a   Fügedi, Gergely ^a   Veresh, Zoltán ^a   Nagy, Bálint ^a   Rigó Jr , János ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

chronic hypertension; gestational hypertension; placental growth factor; preeclampsia; superimposed preeclampsia

Indexed keywords

PLACENTAL GROWTH FACTOR;

ADULT; ARTICLE; CHRONIC HYPERTENSION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; FEMALE; GESTATIONAL AGE; HELLP SYNDROME; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PLACENTAL GROWTH FACTOR TEST; PREECLAMPSIA; PREMATURE LABOR; SUPERIMPOSED PREECLAMPSIA;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY PROTEINS; RETROSPECTIVE STUDIES;

EID: 84877311678     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2012.206     Document Type: Article

References (29)

1. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1-S22.
2. Walker JJ. Pre-eclampsia. Lancet 2000; 356: 1260-1265.
3. Douglas KA, Redman CW. Eclampsia in the United Kingdom. BMJ 1994; 309: 1395-1400.
4. Sibai BM, Ramadan MK, Usta I, Salama M, Mercer BM, Friedman SA. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993; 169: 1000-1006.
5. Hauth JC. Preeclampsia-Eclampsia, In Chesley's Hypertensive Disorders in Pregnancy 2nd (eds). Appleton & Lange, Stamford, Connecticut, 1999, pp 169-199.
6. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of pre-eclampsia. N Engl J Med 2004; 350: 672-683.
7. Knudsen UB, Kronborg CS, von Dadelszen P, Kupfer K, Lee S-W, Vittinghus E, Allen JG, Redman CW. A single rapid point of care placental growth factor determination as an aid in the diagnosis of preeclampsia. Pregn Hypertens 2012; 2: 8-15.
8. Ohkuchi A, Hirashima C, Matsubara S, Takahashi K, Matsuda Y, Suzuki M. Threshold of soluble fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia. Hypertension 2011; 58: 859-866.
9. Hertig A, Berkane N, Lefevre G, Toumi K, Marti HP, Capeau J, Uzan S, Rondeau E. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004; 50: 1702-1703.
10. McKeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004; 191: 1240-1246.
11. Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, Crombleholme WR, Ness RB, Roberts JM, Hubel CA. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005; 90: 4895-4903.
12. Kim SY, Ryu HM, Yang JH, Kim MY, Han JY, Kim JO, Chung JH, Park SY, Lee MH, Kim DJ. Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia. J Korean Med Sci 2007; 22: 873-877.
13. Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998; 179: 1539-1544.
14. Reuvekamp A, Velsing-Aarts FV, Poulina IE, Capello JJ, Duits AJ. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 1999; 106: 1019-1022.
15. Livingston JC, Chin R, Haddad B, McKinney ET, Ahokas R, Sibai BM. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol 2000; 183: 1554-1557.
16. Sunderji S, Gaziano E, Wothe D, Rogers LC, Sibai B, Karumanchi SA, Hodges-Savola C. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 2010; 202: 40.e1-40.e7.
17. Redman C, Lodge T, Meacher H, Marks C, Simms C, Sargent I. Triages PlGF test: point-of-care assay of plasma placental growth factor to diagnose preeclampsia. Adv Perinat Med 2010, Proceedings(ECPM) 181-185.
18. Ohkuchi A, Hirashima C, Suzuki H, Takahashi K, Yoshida M, Matsubara S, Suzuki M. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res 2010; 33: 422-427.
19. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, Gotsch F, Edwin SS, Gomez R, Yeo L, Conde-Agudelo A, Hassan SS. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and antiangiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009; 22: 1021-1038.
20. Lim JH, Kim SY, Park SY, Yang JH, Kim MY, Ryu HM. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol 2008; 111: 1403-1409.
21. Molvarec A, Szarka A, Walentin S, Szucs E, Nagy B, Rigo Jr J. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertens Res 2010; 33: 892-898.
22. Powers RW, Jeyabalan A, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, Lindheimer MD, Sibai B, Landon M, Miodovnik M. Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One 2010; 5: e13263.
23. Nadarajah VD, Min RG, Judson JP, Jegasothy R, Ling EH. Maternal plasma soluble fmslike tyrosine kinase-1 and placental growth factor levels as biochemical markers of gestational hypertension for Malaysian mothers. J Obstet Gynaecol Res 2009; 35: 855-863.
24. Khalil A, Muttukrishna S, Harrington K, Jauniaux E. Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS One 2008; 3: e2766.
25. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010; 122: 478-487.
26. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010; 202: 161.e1-161.e11.
27. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, Dong Z, Tarca A, Gaurav B, Hassan SS. Maternal plasma concentrations of angiogenic/antiangiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011; 24: 1187-1207.
28. De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, Endoglin D'AnnaR. PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008; 87: 837-842.
29. Benton S, Hu Y, Xie F, Kupfer K, Lee SW, Magee L, von Dadelszen P. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol 2011; 205: 469.e1-469.e8.